New in Regulation and Government

How to succeed in a stakeholder-driven environment

16 May 2013 / By Tim / Featured on app, Market Access, Regulation and Government / 0 comments

Pharmaceutical companies must supply convincing evidence of a new drug’s value if it is to achieve attractive price and reimbursement levels, according to a report [...]

 

More in Regulation and Government

• 

  Italian regulation of ‘unproven’ stem cell therapies ‘of global concern’, write scientists

  13 May 2013 / By Tim / Featured on app, Regenerative Medicine, Regulation and Government / 0 comments

   
• 

  Cipla launches etanercept biosimilar in India, but is it likely to overthrow Enbrel?

  3 May 2013 / By Tim / Biosimilars, Featured on app, Regulation and Government / 0 comments

   
• 

  Top 5 Most Surprising Pharma Regulatory Agency Rejections

  29 April 2013 / By Tim / Drug Safety, Featured on app, Regulation and Government / 0 comments

   
• 

  Top 5 Presentations from Last year’s World Orphan Drug Congress Europe

  25 April 2013 / By Matt Turner / Market Access, Orphan Drugs, Partnering & Investment, Regulation and Government / 0 comments

   
• 

  Which 2 drugs are on Ireland’s new “preferred drugs” list?

  22 April 2013 / By Tim / Featured on app, Market Access, Regulation and Government / 0 comments

   
• 

  Discounts needed to access China pharma market

  10 April 2013 / By Tim / Featured on app, Market Access, Regulation and Government / 0 comments

   
• 

  Indian court denies Merck interim relief in Glenmark diabetes patent case

  5 April 2013 / By Tim / Featured on app, Regulation and Government / 0 comments

   
• 

  Johnson & Johnson’s first-of-a-kind diabetes drug Invokana gets the FDA green light

  3 April 2013 / By Tim / Featured on app, Regulation and Government / 0 comments

   
• 

  Novartis fails to secure Glivec patent in India

  2 April 2013 / By Tim / Featured on app, Market Access, Regulation and Government / 0 comments

   
• 

  First US state introduces biosimilars law

  27 March 2013 / By Tim / Featured on app, Regulation and Government / 0 comments